Product
UGN-102
Aliases
UGN-102 (mitomycin) for intravesical solution
4 clinical trials
2 indications
Indication
Bladder CancerIndication
Bladder Urothelial CarcinomaClinical trial
A Phase 3b, Open-Label, Single-Arm, Multicenter Study to Assess the Feasibility of Home Instillation of UGN-102 for Treatment of Patients With Low-Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC) at Intermediate Risk (IR) of RecurrenceStatus: Completed, Estimated PCD: 2023-02-02
Clinical trial
A Phase 2b, Single-Arm, Multicenter Trial to Evaluate the Efficacy and Safety of UGN-102 as Primary Chemoablative Therapy in Patients With Low Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC) at Intermediate Risk of RecurrenceStatus: Completed, Estimated PCD: 2020-01-03
Clinical trial
A Randomized, Controlled, Open-Label Study of the Efficacy, Durability, and Safety of UGN-102 With or Without TURBT in Patients With Low Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (LG IR NMIBC)Status: Terminated, Estimated PCD: 2023-03-17
Clinical trial
A Phase 3, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-102 as Primary Chemoablative Therapy in Patients With Low Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC) at Intermediate Risk (IR) of RecurrenceStatus: Active (not recruiting), Estimated PCD: 2023-04-26